Skip to main content
main-content

30.04.2016 | Original Research | Ausgabe 3/2016

Journal of Radiation Oncology 3/2016

Comorbidity and androgen deprivation therapy use in men undergoing high-dose radiation for unfavorable-risk prostate cancer

Zeitschrift:
Journal of Radiation Oncology > Ausgabe 3/2016
Autoren:
Michael A. Dyer, Ming-Hui Chen, Michelle H. Braccioforte, Brian J. Moran, Anthony V. D’Amico

Abstract

Purpose

Because survival may be shortened in prostate cancer (PC) patients with moderate/severe comorbidity receiving androgen deprivation therapy (ADT), we explored if comorbidity predicts ADT use in those with unfavorable-risk PC.

Methods

Between 10/1997 and 5/2013, 3366 men with unfavorable-intermediate- (70.7 %) or high-risk (29.3 %) PC were treated at the Chicago Prostate Cancer Center using brachytherapy with/without neoadjuvant external-beam radiation therapy (EBRT) and/or ADT. Multivariable logistic regression analysis was performed to evaluate whether history of heart failure and/or myocardial infarction (CHF/MI) was associated with decreased odds of ADT use in men with unfavorable-intermediate- or high-risk PC, adjusting for age, PC prognostic factors, year of brachytherapy, and EBRT use.

Results

Among patients with unfavorable-intermediate-risk PC, 31.2 % received ADT. Among those with high-risk PC, 38.3, 12.3, and 4.8 % received >0–6, >6–18, and >18 months of ADT, respectively. In men with unfavorable-intermediate-risk PC, history of CHF/MI was not significantly associated with decreased odds of ADT use (p = 0.49), but odds of ADT use decreased significantly over the study period, i.e., by year of brachytherapy (adjusted odds ratio [95 % confidence interval] (AOR [95%CI]) = 0.96 [0.94, 0.98], p = 0.0009). Similarly, in men with high-risk PC, history of CHF/MI was not significantly associated with odds of decreased ADT duration (all p values > 0.71), but odds of ADT use of various durations decreased over the years of the study period (AOR [95%CI] = 0.87 [0.83, 0.91], p < 0.0001; AOR [95%CI] = 0.93 [0.87, 0.99], p = 0.023; and AOR [95%CI] = 0.92 [0.83, 1.01], p = 0.089, for >0–6; >6–18; and >18 months of ADT use, respectively, compared to no ADT).

Conclusion

While neoadjuvant ADT use decreased over the study period in men with unfavorable-risk PC undergoing brachytherapy, ADT use was not less likely in those with a history of CHF/MI.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2016

Journal of Radiation Oncology 3/2016 Zur Ausgabe
  1. Sie können e.Med Radiologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise